Schizophrenia Pipeline: Analysis of 90+ key pipeline therapies, 90+ key pharma competitors, unmet needs, and opportunities
Over 90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly. Out of emerging therapies, AVP-786 is in Phase II/III stage of trials. Similarly, MK-8189 is undergoing Phase II developmental phase for Schizophrenia. Schizophrenia pipeline therapies in the early stages of development include CAD-9303, and In December 2020, FDA assigns PDUFA action date of (01/06/2021) for ALKS 3831 for Schizophrenia and Bipolar disorders. In June 2020, Neurocrine Biosciences and ...
Source: globenewswire.com